Royal Park Vaccination Plant

The Royal Park Vaccination Plant in Erbil, KRG, Iraq will comprise two phases. The first phase will target the production of childhood vaccines and other vaccines for diseases that are common in that region. It is estimated to serve 14 million people. The second phase will expand the plant to accommodate vaccines for additional 14-18 million people.

The plant will be designed using modular systems from the United States. McMullan International is currently arranging for its financing from the EXIM Bank of the United States. McMullan International has also assembled a specialty architectural and engineering team that includes Page, Hargrove & Associates Inc., Interface Engineering, and McMullan & Associates, Inc. We anticipate that project design will start August 2021 and construction will start in September 2022.